Ablynx entered into research collaboration and license agreement with Wyeth Pharmaceuticals to discover, develop and commercialize nanobodies targeting TNF-alpha and its receptors in multiple therapeutic areas. The deal could be worth up to US$212.5 M to Ablynx if specific milestones and sales targets are met.